Cargando…

Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma

BACKGROUND: Increasing evidence indicates that rapamycin could be used as a potential glucocorticoid (GC) sensitizer in lymphoblastic malignancies via genetic prevention of 4E-BP1 phosphorylation. Interestingly, we found that combined rapamycin with dexamethasone can effectively reverse GC resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Ling, Xie, Liping, Zuo, Chuan, Ma, Zhigui, Zhang, Yanle, Zhu, Yiping, Gao, Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506760/
https://www.ncbi.nlm.nih.gov/pubmed/26189041
http://dx.doi.org/10.1186/s12885-015-1535-z
_version_ 1782381728203014144
author Gu, Ling
Xie, Liping
Zuo, Chuan
Ma, Zhigui
Zhang, Yanle
Zhu, Yiping
Gao, Ju
author_facet Gu, Ling
Xie, Liping
Zuo, Chuan
Ma, Zhigui
Zhang, Yanle
Zhu, Yiping
Gao, Ju
author_sort Gu, Ling
collection PubMed
description BACKGROUND: Increasing evidence indicates that rapamycin could be used as a potential glucocorticoid (GC) sensitizer in lymphoblastic malignancies via genetic prevention of 4E-BP1 phosphorylation. Interestingly, we found that combined rapamycin with dexamethasone can effectively reverse GC resistance in 4E-BP1 null lymphoma cells. In this study, we investigated the potential link between mTOR/p70S6K signaling pathway, glycolysis, autophagy and GC resistance. METHODS: Antitumor effects of the combination of rapamycin and dexamethasone were evaluated on cell viability by MTT assay and in vivo studies, on cell cycle and apoptosis by flow cytometry, on autophagy by western blot, MDC staining and transmission electron microscopy and on cell signaling by western blot. Moreover, to test whether inhibiting glycolysis is the core mechanism in rapamycin restoring GC sensitivity, we took glycolysis inhibitor 2-deoxyglucose to replace rapamycin and then evaluated the antitumor effects in vitro. RESULTS: Raji cells are resistant to rapamycin (IC(50) > 1000 nM) or dexamethasone (IC(50) > 100 μM) treatment alone. The combination of rapamycin and dexamethasone synergistically inhibited the viability of Raji cells in vitro and in vivo by inducing caspase-dependent and -independent cell death and G(0)/G(1) cell cycle arrest. These effects were achieved by the inhibition of mTOR/p70S6K signaling pathway, which led to the inhibition of glycolysis and the induction of autophagy. Pretreatment with pan-caspase inhibitor z-VAD-fmk or autophagy inhibitor 3-MA failed to protect the cells from combined treatment-induced death. Glycolysis inhibitor combined with dexamethasone produced a similar antitumor effects in vitro. CONCLUSIONS: Inhibition of mTOR/p70S6K/glycolysis signaling pathway is the key point of therapy in reversing GC resistant in Burkitt lymphoma patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1535-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4506760
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45067602015-07-20 Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma Gu, Ling Xie, Liping Zuo, Chuan Ma, Zhigui Zhang, Yanle Zhu, Yiping Gao, Ju BMC Cancer Research Article BACKGROUND: Increasing evidence indicates that rapamycin could be used as a potential glucocorticoid (GC) sensitizer in lymphoblastic malignancies via genetic prevention of 4E-BP1 phosphorylation. Interestingly, we found that combined rapamycin with dexamethasone can effectively reverse GC resistance in 4E-BP1 null lymphoma cells. In this study, we investigated the potential link between mTOR/p70S6K signaling pathway, glycolysis, autophagy and GC resistance. METHODS: Antitumor effects of the combination of rapamycin and dexamethasone were evaluated on cell viability by MTT assay and in vivo studies, on cell cycle and apoptosis by flow cytometry, on autophagy by western blot, MDC staining and transmission electron microscopy and on cell signaling by western blot. Moreover, to test whether inhibiting glycolysis is the core mechanism in rapamycin restoring GC sensitivity, we took glycolysis inhibitor 2-deoxyglucose to replace rapamycin and then evaluated the antitumor effects in vitro. RESULTS: Raji cells are resistant to rapamycin (IC(50) > 1000 nM) or dexamethasone (IC(50) > 100 μM) treatment alone. The combination of rapamycin and dexamethasone synergistically inhibited the viability of Raji cells in vitro and in vivo by inducing caspase-dependent and -independent cell death and G(0)/G(1) cell cycle arrest. These effects were achieved by the inhibition of mTOR/p70S6K signaling pathway, which led to the inhibition of glycolysis and the induction of autophagy. Pretreatment with pan-caspase inhibitor z-VAD-fmk or autophagy inhibitor 3-MA failed to protect the cells from combined treatment-induced death. Glycolysis inhibitor combined with dexamethasone produced a similar antitumor effects in vitro. CONCLUSIONS: Inhibition of mTOR/p70S6K/glycolysis signaling pathway is the key point of therapy in reversing GC resistant in Burkitt lymphoma patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1535-z) contains supplementary material, which is available to authorized users. BioMed Central 2015-07-20 /pmc/articles/PMC4506760/ /pubmed/26189041 http://dx.doi.org/10.1186/s12885-015-1535-z Text en © Gu et al. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Gu, Ling
Xie, Liping
Zuo, Chuan
Ma, Zhigui
Zhang, Yanle
Zhu, Yiping
Gao, Ju
Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma
title Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma
title_full Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma
title_fullStr Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma
title_full_unstemmed Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma
title_short Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma
title_sort targeting mtor/p70s6k/glycolysis signaling pathway restores glucocorticoid sensitivity to 4e-bp1 null burkitt lymphoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506760/
https://www.ncbi.nlm.nih.gov/pubmed/26189041
http://dx.doi.org/10.1186/s12885-015-1535-z
work_keys_str_mv AT guling targetingmtorp70s6kglycolysissignalingpathwayrestoresglucocorticoidsensitivityto4ebp1nullburkittlymphoma
AT xieliping targetingmtorp70s6kglycolysissignalingpathwayrestoresglucocorticoidsensitivityto4ebp1nullburkittlymphoma
AT zuochuan targetingmtorp70s6kglycolysissignalingpathwayrestoresglucocorticoidsensitivityto4ebp1nullburkittlymphoma
AT mazhigui targetingmtorp70s6kglycolysissignalingpathwayrestoresglucocorticoidsensitivityto4ebp1nullburkittlymphoma
AT zhangyanle targetingmtorp70s6kglycolysissignalingpathwayrestoresglucocorticoidsensitivityto4ebp1nullburkittlymphoma
AT zhuyiping targetingmtorp70s6kglycolysissignalingpathwayrestoresglucocorticoidsensitivityto4ebp1nullburkittlymphoma
AT gaoju targetingmtorp70s6kglycolysissignalingpathwayrestoresglucocorticoidsensitivityto4ebp1nullburkittlymphoma